PMID- 16948806
OWN - NLM
STAT- MEDLINE
DCOM- 20070329
LR  - 20220330
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 24
IP  - 6
DP  - 2006 Sep 15
TI  - Discontinuation of proton pump inhibitors in patients on long-term therapy: a 
      double-blind, placebo-controlled trial.
PG  - 945-54
AB  - BACKGROUND: The proportion of proton pump inhibitor users on long-term therapy 
      who can discontinue proton pump inhibitor (PPI) medication without developing 
      symptoms is unknown. AIM: To determine the proportion of patients on long-term 
      PPI therapy who are able to discontinue PPIs without developing symptoms. 
      METHODS: Patients on long-term PPIs, without a history of peptic ulcer or 
      esophagitis underwent upper endoscopy. Patients were randomized double-blindly to 
      taper down or continue a constant dosage of omeprazole for three weeks. 
      Thereafter, all patients discontinued PPIs. RESULTS: Of the 97 patients enrolled, 
      had used PPIs for 48 months, 78% had GERD. A total of 27% did not use PPIs during 
      the year after discontinuation, 31% of the patients randomized to tapering 
      discontinued PPIs and 22% of those who did not could discontinue therapy (NS). 
      Gastro-oesophageal reflux disease (GERD) patients were more prone to continue 
      PPIs than non-GERD patients. Only 16 (21%) of GERD patients were off PPIs vs. 48% 
      of patients without GERD (p < 0.05). Serum gastrin was higher at baseline in GERD 
      patients who resumed PPIs versus non-resumers (p < 0.05). GERD and serum gastrin 
      were independent predictors of PPI requirement. CONCLUSIONS: Discontinuation of 
      PPI was successful in 27% of long-term PPI users. GERD patients had more 
      difficulty discontinuing PPIs than non-GERD patients.
FAU - Bjornsson, E
AU  - Bjornsson E
AD  - Department of Internal Medicine, Section of Gastroenterology and Hepatology, 
      Sahlgrenska University Hospital, Gothenburg, Sweden. einar.bjornsson@medic.gu.se
FAU - Abrahamsson, H
AU  - Abrahamsson H
FAU - Simren, M
AU  - Simren M
FAU - Mattsson, N
AU  - Mattsson N
FAU - Jensen, C
AU  - Jensen C
FAU - Agerforz, P
AU  - Agerforz P
FAU - Kilander, A
AU  - Kilander A
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Gastrins)
RN  - 0 (Proton Pump Inhibitors)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - Aged
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Dyspepsia/blood/drug therapy
MH  - Enzyme Inhibitors/*administration & dosage
MH  - Female
MH  - Gastrins/blood
MH  - Gastroesophageal Reflux/blood/*drug therapy
MH  - Humans
MH  - Long-Term Care
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/administration & dosage
MH  - *Proton Pump Inhibitors
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Withholding Treatment
EDAT- 2006/09/05 09:00
MHDA- 2007/03/30 09:00
CRDT- 2006/09/05 09:00
PHST- 2006/09/05 09:00 [pubmed]
PHST- 2007/03/30 09:00 [medline]
PHST- 2006/09/05 09:00 [entrez]
AID - APT3084 [pii]
AID - 10.1111/j.1365-2036.2006.03084.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2006 Sep 15;24(6):945-54. doi: 
      10.1111/j.1365-2036.2006.03084.x.